The diagnostic specialist for serious infectious diseases, cube dx, won Austria’s most highly endowed R&D prize this year, the Houska Prize, awarded by B&C Holding/Foundation. Founded in 2015, cube dx will launch a crowdinvesting campaign in February/March following the FFG funding of 500k that has just been granted. These funds will give the financially sound target a further boost to growth. In 2021/2022, Cube dx generated total sales of EUR 4.3 million and a pre-tax profit of EUR 1.1 million. C4 already advised the founders Christof Reschreiter and Dr. Bernhard Ronacher on an earlier transaction and will structure a EUR 5 million crowdinvesting and equity transaction for cube dx in 2025.
St. Valentin, December 2023
